VAL.Lライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 7月 2024 @ 17:59):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

Stats
本日の出来高	194 542
平均出来高	1.86M
時価総額	4.17M
EPS	£-0.00980 ( Q4 \| 2023-12-31 )
次の収益日	( £0 ) 2024-08-21
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.570 (Sector) 0 (Industry) 0
ATR14	£0.104 (3.30%)

AMYT.L -11.73%

APH.L -0.04%

AVCT.L -0.99%

AZN.L -0.43%

BMK.L 2.34%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -0.80%

DPH.L 0.05%

EAH.L 3.20%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -4.29%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 3.33%

GNS.L 1.44%

GSK.L -0.53%

HCM.L -0.36%

HEMO.L -2.90%

HIK.L -0.53%

IMM.L 4.81%

INDV.L -0.09%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.27%

PRM.L -4.82%

PRTC.L 0.55%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 10.11%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 4.05%

STX.L 2.70%

TILS.L 8.33%

TRX.L -2.06%

VAL.L 0.00%

VEC.L 0.00%

相関 (AI algo v.1.1b): Overvalued: -0.15% £3.15 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ValiRx PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ValiRx PLC 財務諸表

Annual	2023
収益:	£9 600.00
総利益:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2023
収益:	£9 600.00
総利益:	£-246 043 (-2 562.95 %)
EPS:	£-0.0201

FY	2022
収益:	£0
総利益:	£-224 268 (0.00 %)
EPS:	£-0.0311

FY	2021
収益:	£0.00
総利益:	£0.00 (0.00 %)
EPS:	£-0.0401

Financial Reports:

No articles found.

ValiRx PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ValiRx PLC

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.